Scientific Publications


 

 

i

Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial

Loke P, Orsini F, Lozinsky AC, Gold M, O’Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK; PPOIT-003 study group. Lancet Child Adolesc Health. 2022 Mar;6(3):171-184.
i

Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials.

Lloyd M, Dunn Galvin A and Tang MLK. (2022) Front Allergy. 2022 Jul 12;3:941020.
i

Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement

Loke P, Hsiao KC, Lozinsky AC, Ashley SE, Lloyd M, Pitkin S, Axelrad CJ, Jayawardana KS, Tey D, Su EL, Robinson M, Leung ASY, Dunn Galvin A, Tang MLK. Clin Exp Allergy. 2022 Jun;52(6):806-811.

i

Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks.

Ashley SE, Jones AC, Anderson D, Holt PG, Bosco A, Tang MLK. Allergy. 2022 Oct;77(10):3015-3027.
i

Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy (PPOIT) in children with peanut allergy.

Hsiao KC, Ponsonby AL, Ashley S, Lee CYY, Jindal L; PPOIT Study Team, Tang MLK. Clin Exp Allergy. 2022 Apr 11. Online ahead of print.
i

Long-term benefit of probiotic peanut oral immunotherapy on quality of life in a randomized trial.

Dunn-Galvin A, Lloyd M, Hsiao KC, Tang MLK; PPOIT-001 study team. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4493-4495.e1